Concepedia

J.T.J.N. Hiltermann

JH

3

Publications

2.9K

Citations

3

H-Index

1997

Active since

Affiliations

Asklepios Fachkliniken München-Gauting(Current)

Hospital Universitario 12 De Octubre

Ospedale Vincenzo Cervello

Okayama University Hospital

AstraZeneca (United States)

J.T.J.N. Hiltermann is an author at Asklepios Fachkliniken München-Gauting specializing in medicine, cancer therapeutics, and lung cancer.

Top concepts

Publications per year

1997–2020

3

Publications

3

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

, , +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

, , +6

The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma.

Zuzana Diamant, J.T.J.N. Hiltermann, E.L. van Rensen et al. · American Journal of Respiratory and Critical Care Medicine · 1997 · 160 citations

, , +14

Rows per page

1–3 of 3